Identifying drug targets for schizophrenia through gene prioritization

Area of Science:

• Genetics
• Neuroscience
• Pharmacology

Background:

• Genome-wide association studies (GWASes) have identified over 250 significant loci and more than 100 genes associated with schizophrenia.
• Previous gene prioritization efforts primarily used locus-based methods, neglecting broader genomic information.
• Accurate gene characterization is crucial for understanding schizophrenia etiology.

Purpose of the Study:

• To more accurately identify genes contributing to schizophrenia etiology.
• To integrate locus-based and genome-wide approaches for comprehensive gene prioritization.

Main Methods:

• Applied a combination of predictive tools to a large GWAS dataset (67,390 cases, 94,015 controls).
• Utilized locus-based methods (fine-mapped coding variants, distance to signals) and genome-wide methods (PoPS, MAGMA, burden tests).
• Validated findings against prior efforts, neurodevelopmental genes, and the PsyOPS tool.

Main Results:

• Prioritized 62 schizophrenia-associated genes, with 41 confirmed by validation methods.
• Identified 9 drug-targeted genes beyond DRD2, including those for glutamatergic, calcium channel, and GABA receptors.
• Found shared loci with addiction GWAS, highlighting genes like PDE4B and VRK2.

Conclusions:

• A high-quality list of 62 genes implicated in schizophrenia development was curated.
• Targeting these genes offers potential for developing novel schizophrenia therapies.
• Genes prioritized for both schizophrenia and addiction warrant further investigation in addiction models for drug development.